Generation Bio GBIO 深 沪
等待开盘 07-09 09:30:00 美东时间
5.34
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.34
- 总市值 3598.38万
- 52周最高 6.95
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.004
- 委 比 0.00%
- 总股本 673.85万
- 历史最高 557.20
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.004
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. appoints Marie Washburn as Senior Vice President and Chief Financial Officer, effective July 13, 2026. With over 20 years of leadership experience in the pharmaceutical and biotech sectors, Washburn previously served as Vice President and Corporate Controller at the company. Her appointment comes as Longeveron anticipates top-line results from its Phase 2b clinical trial for laromestrocel in treating Hypoplastic Left Heart Syndrom...
07-06 20:05
XOMA Royalty Completes Generation Bio Acquisition and Merger
Xoma ( ($XOMA) ) has provided an announcement. On February 6, 2026, XOMA Royalt...
02-10 05:56
XOMA Royalty übernimmt Generation Bio für 4,29 Dollar je Aktie
XOMA Royalty übernimmt Generation Bio für 4,29 Dollar je Aktie XOMA Royalty Corporation hat das Übernahmeangebot für alle ausstehenden Aktien von Generation Bio abgeschlossen und die Übernahme des Unternehmens vollzogen. Generation Bio-Aktionäre erhielten 4,2913 US-Dollar je Aktie in bar sowie eine
02-09 22:53
XOMA Royalty Completes Acquisition of Generation Bio for $4.29 Per Share
XOMA Royalty Completes Acquisition of Generation Bio for $4.29 Per Share XOMA Royalty Corporation has completed its previously announced acquisition of Generation Bio, Inc. The transaction followed a successful tender offer, with shareholders of Generation Bio receiving $4.2913 per share in cash plu
02-09 22:53
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
XOMA Royalty completed its acquisition of Generation Bio by paying $4.2913 per share in cash plus a contingent value right. Approximately 70% of shares were tendered, meeting the conditions for the takeover. Following the acquisition, Generation Bio merged into XOMA's subsidiary, becoming a wholly owned entity. Its shares ceased trading on Nasdaq and will be delisted.
02-09 14:53
Takeda, XOMA ink new royalty agreement; amend existing deal
XOMA Royalty Corporation (XOMA) on Tuesday announced that it reached a new royalty sharing transaction with Takeda (TAK) and amended its existing royalty sharing agreement for the Japanese drugmaker’s...
2025-12-30 21:14
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
BRIEF-Nodthera Appoints Geoff Mcdonough, M.D., As Independent Board Member
Dec 16 (Reuters) - Generation Bio Co GBIO.O: NODTHERA APPOINTS GEOFF MCDONOUGH, M.D., AS INDEPENDENT BOARD MEMBER Source text: ID:nGNX9xQ43s Further company coverage: GBIO.O ((Reuters.Briefs@thomsonre...
2025-12-16 22:42
XOMA Royalty to acquire Generation Bio
XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...
2025-12-16 06:28
XOMA Royalty To Acquire Generation Bio Co. For A Cash Price Of $4.2913 Per Share At The Closing Of The Merger
XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has entered into an agreement to acquire Generation Bio Co. ("Generation Bio") (NASDAQ:GBIO) for a cash price of
2025-12-16 06:02
